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Correction
In our study to evaluate the diagnostic accuracy of FENO
measurement with NioxMino® for the diagnosis of asthma
in general practice, we found the cut-off at FENO £ 12 ppb
to rule out mild and moderate to severe asthma with a
negative predictive value of 81% (95%CI 64–91%) [1].
We oriented ourselves at the already established value of
12 ppb [2]. However, we overlooked in the ROC analysis
that the overall diagnostic accuracy improves slightly
when the cut-off is chosen at FENO £ 16 ppb (revised table
two) [see table 1]. Negative likelihood ratio was 0.38
(95%CI 0.22–0.64) and positive likelihood ratio was 1.76
(95%CI 1.37–2.26) using the 16 ppb cut-off (revised table
three) [see Table 2].
In patients with unsuspicious spirometric results (n = 101;
not in table) there was no improvement of diagnostic
accuracy. The best cut-off point was at FENO £ 16 ppb
again. In this diagnostic group sensitivity was 78%
(95%CI 63–89%), specificity was 45% (95%CI 34–57%),
PPV was 45% (95%CI 34–57%) and NPV was 78%
(95%CI 63–89%).
Table two [see Table 1 below] illustrates that the patient
group with correctly excluded asthma by FENO measure-
ment increases at FENO £ 16 ppb; and the range of the con-
fidence interval narrows. Thus three patients need to be
diagnosed for excluding asthma in order to save one bron-
chial provocation test when FENO £ 16 ppb is used as the
cut-off point. With FENO £ 12 ppb five patients need to be
tested in order to exclude asthma in one of them. There-
fore, we suggest choosing FENO £ 16 ppb to rule out mild
and moderate to severe asthma. This improves diagnostic
efficiency compared to the £ 12 ppb cut-off point.
We would like to correct the following points in the man-
uscript:
In the Results section of the Abstract lines 6–7 should
read as:
"16 ppb (n = 68; 42.5%), sensitivity was 79% (95%CI 67–
88), specificity 55% (95%CI 45–64), PPV 50% (95%CI
40–60), NPV 82% (95%CI 72–90)".
Also in line 7, "Three" should say "Two".
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Respiratory Research 2009, 10:64 http://respiratory-research.com/content/10/1/64In the Conclusion section of the Abstract, in line 2,
"FENO £ 12 ppb" should say "FENO £ 16 ppb".
In the Sensitivity analyses section, in line 2 of the third
paragraph, "FENO £ 12 ppb" should say "FENO £ 16 ppb",
"81% (95% CI 64–91)" should say "82% (95% CI 72–
90)" and "34" should say "68". In line 3, "FENO £ 12 ppb"
should say "FENO £ 16 ppb" and "five" should say "three".
In line 4 "12 ppb" should say "16 ppb". The sentence
starting in line 5 and ending in line 6 should read: "Sensi-
tivity was 78% (95%CI 63–89), specificity was 45%
(95%CI 34–57), PPV was 45% (95%CI 34–57), NPV was
78 (95%CI 63–89)". In line 6, "16 (15.8%)" should say
"37 (36.6%)", "FENO £ 12 ppb" should say "FENO £ 16
ppb" and "increased up to 82% (95%CI 64–92)" should
say "was 77% (95%CI 61–88)".
In the Discussion section, in line 4, "81%" should say
"82%" and in line 5, "FENO £ 12" should say "FENO £ 16"
In the second paragraph, in line 1, "five" should say
"three". In line 5, "16 patients had FENO £ 12 ppb" should
say "37 patients had FENO £ 16 ppb". Also in line 5,
"three" should say "two" and in lines 11 and 12 "FENO £
12 ppb" should say ""FENO £ 16 ppb" and 12 ppb<FENO
should say 16 ppb<FENO.
In the third line of the third paragraph "12 to 46 ppb"
should say "16 to 46 ppb" and in the seventh line, the sec-
Table 1: Sensitivity (sens), specificity (spec), positive predictive value (PPV) and negative predictive value (NPV) at different cut-off 
points (n = 160); unit of FENO is parts per billion
Asthma diagnoses FENO sens [%] (95%CI) spec [%] (95%CI) PPV [%] (95%CI) NPV [%] (95%CI) n
Borderline BHR mild BHR moderate to 
severe BHR positive bronchodilator 
reversibility
(n = 75)*
> 12 85 (76–92) 24 (16–34) 50 (41–58) 65 (47–79) 126
> 16 69 (58–79) 53 (42–63) 57 (46–66) 66 (54–76) 92
> 20 64 (53–74) 58 (47–77) 57 (47–67) 65 (53–74) 82
> 35 32 (25–42) 84 (74–90) 63 (47–77) 58 (49–67) 38
> 46 32 (23–43) 93 (85–97) 80 (63–91) 61 (52–69) 30
> 76 13 (7–23) 100 (96–100) 100 (72–100) 57 (49–65) 11
Mild BHR moderate to severe BHR 
positive bronchodilator reversibility
(n = 58)§
> 12 90 (79–95) 25 (17–34) 40 (32–49) 81 (64–91) 126
> 16 79 (67–88) 55 (45–64) 50 (40–60) 82 (72–90) 92
> 20 67 (54–78) 62 (52–71) 50 (39–61) 77 (67–85) 82
> 35 36 (25–49) 83 (75–89) 55 (40–70) 70 (61–77) 38
> 46 36 (25–49) 91 (84–95) 70 (52–83) 72 (63–79) 30
> 76 17 (10–29) 100 (96–100) 100 (72–100) 68 (60–75) 11
*prevalence of asthma = 46.9%, prevalence of 'no asthma' = 53.1%
§ prevalence of asthma = 36,3%, prevalence of 'no asthma' = 63.7%
Table 2: Likelihood ratio at different cut-off points (n = 160); unit of FENO is parts per billion; LR+ is positive likelihood ratio, LR- is 
negative likelihood ratio
Asthma diagnoses FENO LR+ (95%CI) LR- (95%CI)
Borderline BHR, mild BHR, moderate to severe BHR, positive bronchodilator reversibility (n = 75) > 12 1.12 (0.96–1.30) 0.62 (0.32–1.21)
> 16 1.47 (1.12–1.93) 0.58 (0.39–0.86)
> 20 1.55 (1.12–2.14) 0.65 (0.47–0.91)
> 35 1.94 (1.09–3.48) 0.81 (0.68–0.98)
> 46 4.53 (1.96–10.49) 0.73 (0.62–0.86)
> 76 not calculable not calculable
Mild BHR, moderate to severe BHR, positive bronchodilator reversibility (n = 58) > 12 1.19 (1.03–1.37) 0.42 (0.18–0.97)
> 16 1.76 (1.37–2.26) 0.38 (0.22–0.64)
> 20 1.76 (1.30–2.39) 0.53 (0.36–0.79)
> 35 2.17 (1.25–3.77) 0.77 (0.62–0.95)
> 46 4.10 (2.02–8.36) 0.70 (0.57–0.86)
> 76 not calculable not calculablePage 2 of 3
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ond half of the sentence that reads "and the difference of
the 95%CI (-9.8 ppb) and 20 ppb is close to our best cut-
off point (12 ppb) to rule out asthma" should not be
there.
In the conclusion section, in line 3 "FENO £ 12 ppb"
should say ""FENO £ 16 ppb" and "three" should say
"two".
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